Echovirus 9, Enterovirus Infections, Meningitis Enterovirus, Meningitis, Viral
Conditions
Keywords
Echovirus 9, Enterovirus, Viral meningitis, Molecular epidemiology, Phylogenetic analysis, RT-PCR, Retrospective study, Surveillance, France, outbreak, Emerging variant, France epidemiology
Brief summary
This study is being done to learn more about enterovirus infections detected in the cerebrospinal fluid of patients at CHU de Brest. Researchers will analyze medical records and laboratory data collected between 2018 and 2024. They will look at how these infections present in patients, and whether a specific virus type, called Echo-9, may be associated with different clinical features or represent an emerging variant.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Days to 100 Years
Healthy volunteers
No
Inclusion criteria
* Cerebrospinal fluid (CSF) sample positive for enterovirus by RT-PCR between January 1, 2018 and December 31, 2024 , performed at the virology laboratory of CHU de Brest. * No documented opposition to the use of medical data for research purposes.
Exclusion criteria
* Patients under legal protection (guardianship, curatorship, etc.) * Refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phylogenetic analysis of Echo-9 strains detected between 2018 and 2024 | January 1, 2018 to December 31, 2024 | Molecular characterization and phylogenetic comparison of Echo-9 strains detected at CHU de Brest and throughout France between January 1, 2018 and December 31, 2024, to identify a possible emerging variant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics of enterovirus-positive CSF cases | January 1, 2018 to December 31, 2024 | Among patients with cerebrospinal fluid samples positive for enterovirus between 2018 and 2024, clinical features will be described, including headache intensity, clinical severity, infection site (CSF, throat, stool, nasopharyngeal samples), and use of morphine. Subgroup comparisons may be conducted according to enterovirus genotype and year of infection, depending on the results of molecular typing. |
| Temporal distribution of enterovirus infections documented at CHU de Brest | January 1, 2018 to December 31, 2024 | Weekly quantification of enterovirus-positive cases (by RT-PCR) detected at CHU de Brest from 2018 to 2024. Comparison with national surveillance data from the French National Reference Center to detect atypical epidemic peaks, with a focus on 2024. |
| Biological characteristics of enterovirus-positive CSF samples | January 1, 2018 to December 31, 2024 | Among patients with cerebrospinal fluid samples positive for enterovirus between 2018 and 2024, biological parameters from positive samples will be described. For cerebrospinal fluid samples, variables include white blood cell count with differential, protein level, and the cerebrospinal fluid to blood glucose ratio. The presence or absence of additional positive samples (throat, stool, nasopharyngeal swabs) will also be documented. |
Countries
France
Outcome results
None listed